| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm |
| Cash burn (monthly) | 812.33 k | 521.92 k | 8.79 mm | 7.47 mm | 7.56 mm | 6.78 mm |
| Cash used (since last report) | 3.27 mm | 2.10 mm | 35.35 mm | 30.06 mm | 30.41 mm | 27.30 mm |
| Cash remaining | 18.16 mm | 19.33 mm | -13.93 mm | -8.64 mm | -8.98 mm | -5.87 mm |
| Runway (months of cash) | 22.4 | 37.0 | -1.6 | -1.2 | -1.2 | -0.9 |
| 13F holders | Current |
|---|---|
| Total holders | 131 |
| Opened positions | 19 |
| Closed positions | 26 |
| Increased positions | 58 |
| Reduced positions | 24 |
| 13F shares | Current |
|---|---|
| Total value | 666.21 bn |
| Total shares | 241.10 mm |
| Total puts | 29.40 k |
| Total calls | 67.60 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| NEA Management | 24.47 mm | $103.76 bn |
| Growth Equity Opportunities 17 | 24.47 mm | $100.33 mm |
| Farallon Capital Partners | 16.65 mm | $60.59 mm |
| Bain Capital Life Sciences Investors | 14.57 mm | $61.76 bn |
| Bain Capital Life Sciences Fund II | 14.57 mm | $69.04 mm |
| TCG Crossover Management | 12.36 mm | $52.42 bn |
| TCG Crossover GP I | 10.00 mm | $31.40 mm |
| BlackRock | 9.40 mm | $39.85 bn |
| Wellington Management | 8.62 mm | $36.57 bn |
| Frazier Life Sciences Management | 8.16 mm | $34.59 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Dec 24 | Hawkins Richard J | Common Stock | Sell | Dispose S | No | No | 3.3211 | 8,000 | 26.57 k | 67,241 |
| 16 Dec 24 | Matthew Pauls | Common Stock | Sell | Dispose S | No | No | 3.3057 | 54,702 | 180.83 k | 1,536,379 |
| 13 Dec 24 | Matthew Pauls | Common Stock | Payment of exercise | Dispose F | No | No | 3.21 | 92,593 | 297.22 k | 1,591,081 |
| 12 Dec 24 | Nevan C Elam | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 62,500 |
| 12 Dec 24 | McCracken Joseph S | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 250,837 |
| 12 Dec 24 | van Es-Johansson An | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 62,500 |
| 12 Dec 24 | Hawkins Richard J | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 75,241 |
| 12 Dec 24 | Matthew Pauls | Common Stock | Grant | Acquire A | No | No | 0 | 400,000 | 0.00 | 1,683,674 |
| 12 Dec 24 | Matthew Pauls | Stock Option Common Stock | Grant | Acquire A | No | No | 3.35 | 900,000 | 3.02 mm | 900,000 |
